Literature DB >> 22982770

A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.

Chun Li1, Bo Liu, Jonathan Chang, Todd Groessl, Matthew Zimmerman, You-Qun He, John Isbell, Tove Tuntland.   

Abstract

Successful drug discovery relies on the selection of drug candidates with good in vivo pharmacokinetic (PK) properties as well as appropriate preclinical efficacy and safety profiles. In vivo PK profiling is often a bottleneck in the discovery process. In this review, we focus on the tiered in vivo PK approaches implemented at the Genomics Institute of the Novartis Research Foundation (GNF), which includes snapshot PK, rapid PK and full PK studies. These in vivo PK approaches are well integrated within discovery research, allow tremendous flexibility and are highly efficient in supporting the diverse needs and increasing demand for in vivo profiling. The tiered in vivo PK studies expedite compound profiling and help guide the selection of more desirable compounds into efficacy models and for progression into development.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2012        PMID: 22982770     DOI: 10.1016/j.drudis.2012.09.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  Tissue Distribution, Excretion, and Interaction With Human Serum Albumin of Total Bioflavonoid Extract From Selaginella doederleinii.

Authors:  Bing Chen; Dafen Xu; Zhijun Li; Yafei Jing; Luping Lin; Shaoguang Li; Liying Huang; Xiuwang Huang; Ailin Liu; Xinhua Lin; Hong Yao
Journal:  Front Pharmacol       Date:  2022-04-29       Impact factor: 5.988

2.  Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.

Authors:  Bruno M D C Godinho; James W Gilbert; Reka A Haraszti; Andrew H Coles; Annabelle Biscans; Loic Roux; Mehran Nikan; Dimas Echeverria; Matthew Hassler; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2017-10-12       Impact factor: 5.486

3.  Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery.

Authors:  Doha Naga; Neil Parrott; Gerhard F Ecker; Andrés Olivares-Morales
Journal:  Mol Pharm       Date:  2022-04-27       Impact factor: 5.364

Review 4.  Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies.

Authors:  E L Andrade; A F Bento; J Cavalli; S K Oliveira; R C Schwanke; J M Siqueira; C S Freitas; R Marcon; J B Calixto
Journal:  Braz J Med Biol Res       Date:  2016-12-12       Impact factor: 2.590

5.  Random Forest Model Prediction of Compound Oral Exposure in the Mouse.

Authors:  Haseeb Mughal; Han Wang; Matthew Zimmerman; Marc D Paradis; Joel S Freundlich
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-26

6.  Targeting Plasmodium PI(4)K to eliminate malaria.

Authors:  Case W McNamara; Marcus Cs Lee; Chek Shik Lim; Siau Hoi Lim; Jason Roland; Oliver Simon; Bryan Ks Yeung; Arnab K Chatterjee; Susan L McCormack; Micah J Manary; Anne-Marie Zeeman; Koen J Dechering; Tr Santha Kumar; Philipp P Henrich; Kerstin Gagaring; Maureen Ibanez; Nobutaka Kato; Kelli L Kuhen; Christoph Fischli; Advait Nagle; Matthias Rottmann; David M Plouffe; Badry Bursulaya; Stephan Meister; Lucia Rameh; Joerg Trappe; Dorothea Haasen; Martijn Timmerman; Robert W Sauerwein; Rossarin Suwanarusk; Bruce Russell; Laurent Renia; Francois Nosten; David C Tully; Clemens Hm Kocken; Richard J Glynne; Christophe Bodenreider; David A Fidock; Thierry T Diagana; Elizabeth A Winzeler
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

Review 7.  Xanthorrhizol: a review of its pharmacological activities and anticancer properties.

Authors:  Seok Fang Oon; Meenakshii Nallappan; Thiam Tsui Tee; Shamarina Shohaimi; Nur Kartinee Kassim; Mohd Shazrul Fazry Sa'ariwijaya; Yew Hoong Cheah
Journal:  Cancer Cell Int       Date:  2015-10-21       Impact factor: 5.722

8.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.

Authors:  Shilpi Khare; Advait S Nagle; Agnes Biggart; Yin H Lai; Fang Liang; Lauren C Davis; S Whitney Barnes; Casey J N Mathison; Elmarie Myburgh; Mu-Yun Gao; J Robert Gillespie; Xianzhong Liu; Jocelyn L Tan; Monique Stinson; Ianne C Rivera; Jaime Ballard; Vince Yeh; Todd Groessl; Glenn Federe; Hazel X Y Koh; John D Venable; Badry Bursulaya; Michael Shapiro; Pranab K Mishra; Glen Spraggon; Ansgar Brock; Jeremy C Mottram; Frederick S Buckner; Srinivasa P S Rao; Ben G Wen; John R Walker; Tove Tuntland; Valentina Molteni; Richard J Glynne; Frantisek Supek
Journal:  Nature       Date:  2016-08-08       Impact factor: 49.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.